ClinicalTrials.gg
CompletedNCT02194933Updated Nov 8, 2018Results posted

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

A Phase 3 interventional study of Brexpiprazole in Schizophrenia With Impulsivity, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-11-08.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
22nd of 28
38 · median 155
Started
2015
with 1 other
Phase 3
16 of 28
none open now
Registered
21st of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 22nd largest by enrollment, is one of 2 that started in 2015, is one of 16 in phase 3, and was the 21st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.

03

Conditions studied

  • Schizophrenia With Impulsivity

Keywords

  • Schizophrenia
  • Mental Disorders, Antipsychotic,
  • Psychotic disorder, Impulsivity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 to 65 years of age, inclusive, at the time of (outpatients only), with a diagnosis of schizophrenia as defined by , Fourth Edition, Text Revision (DSM-IV-TR) criteria and confirmed by both the M.I.N.I. for Schizophrenia and Psychotic Disorders Studies, and an adequate clinical psychiatric evaluation.
  • Have a CGI-S score of ≤ 4 (moderately ill) at screening and baseline.
  • Have a score of ≤ 4 (moderate) on PANSS item G8 (uncooperativeness) at screening and baseline.
  • Have a BIS-11 score of ≥ 50 at screening and baseline.
  • Willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.
  • Are stable on their current oral antipsychotic medication (no changes within the last month) and are able to meet protocol-required washouts of their current antipsychotic medication.
  • Have received previous outpatient antipsychotic treatment at an adequate dose (at least minimal recommended dose for the treatment of schizophrenia according to the manufacturer labeling) for an adequate duration (at least 6 weeks) and showed a previous good response to such antipsychotic treatment (other than clozapine) in the last 12 months, according to the investigator's opinion.
  • Subjects with eyesight that is sufficient to be able to see visual displays, or correctable with magnet-compatible glasses or contact lenses.
  • Subjects fluent in English

Exclusion criteria

Exclusion Criteria:

  • Are presenting with schizophreniform or with a first episode of schizophrenia based on the clinical judgment of the investigator.
  • Have been hospitalized for psychotic symptoms within the previous 6 months.
  • Have a current Axis I primary diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder (OCD) or panic disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders, or mental retardation.
  • Have worsening of ≥ 20% in total PANSS score between the screening and baseline assessments.
  • Experiencing a deterioration in clinical status or an acute exacerbation of schizophrenia in the opinion of the Investigator.
  • Experiencing acute onset of depressive symptoms within the past 30 days, according to the investigator's opinion.
  • Answer "Yes" on the Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Answer "Yes" on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria for this C-SSRS Item 5 occurred within the last 6 months OR Answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR who, in the opinion of the investigator, present a serious risk of suicide.
  • Have a history of stroke.
  • to magnetic resonance imaging (MRI) such as metal prostheses, pacemakers, claustrophobia, movement disorders, waist circumference more than 56 inches or head circumference more than 29 inches, color blindness, significant tremors, or history of head injury or prolonged unconsciousness
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Brexpiprazole 2 mg

    Brexpiprazole 2 mg/day, once daily dose, tablet, orally

    Drug: Brexpiprazole

  • Experimental
    Brexpiprazole 4 mg

    Brexpiprazole 4 mg/day, once daily dose, tablet, orally

    Drug: Brexpiprazole

Interventions

  • Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks

    Also known as: OPC-34712

06

What researchers measure

Primary outcomes

  1. Change From Baseline Brain Activation in the Ventrolateral Prefrontal Cortex (VLPFC) Based on Change From Baseline to Week 6 in fMRI Blood Oxygen-level Dependent (BOLD) Activation Score in the Right VLPFC During Performance of the Go/No-go Task

    To evaluate the effect of brexpiprazole on brain regions activated by impulsive behavior (specifically, activation of the right VLPFC). Assessed by fMRI measurements taken when participants perform tasks designed to assess impulsivity. The tasks to be performed in the scanner included the Go/No-go. Participants were asked to press a button as fast as they could to Stimulus A (eg, neutral face) that appeared on the screen (Go trials) \& to NOT press a button to Stimulus B (eg, happy face) that appeared on the screen (No-go trials). The Go trials were presented at a higher frequency (eg, 75% of the time) than the No-go trials to build up a pre-potent response/response bias. Scores were not bounded by a minimum or maximum range, higher fMRI BOLD activation scores indicate increased brain blood flow, which reflects brain activity.

    Time frame: At baseline (Day 0), and week 6 (Day 42) of the treatment phase

  2. Change From Baseline Brain Activation in the VLPFC Based on Change From Baseline to Week 6 in fMRI BOLD Activation Score in the Right VLPFC During Performance of the SSRT Task

    To evaluate the effect of brexpiprazole on brain regions activated by impulsive behavior (specifically, activation of the right VLPFC). Assessed by fMRI measurements taken when participants performed impulsivity assessment tasks. A white circle was shown for 500ms, followed by a left (\<)/right (\>) arrow. When an arrow was presented, participants responded as fast as possible with their index/middle finger. A titration procedure with 4 staircases started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms to determine participant's SSRT. The tasks included 3 runs with 166 repetition times (TRs), TR=2s; 5 minutes, 32 seconds/run; 96 go trials, 32 stop trials/ run. The total task duration was 16 minutes \& 36 seconds. Scores were not bounded by a minimum or maximum range, higher fMRI BOLD activation scores indicate increased brain blood flow, which reflects brain activity.

    Time frame: At baseline (Day 0), and week 6 (Day 42) of the treatment phase

Secondary outcomes

  1. Change From Baseline to Week 3 in fMRI BOLD Activation Score in the Right VLPFC, Scanned by fMRI During Performance of Tasks Associated With Impulsivity (SSRT Task, Go/No-go Task)

    Go/No-go: Participants were to press button fast to Stimulus A (neutral face) (Go trials) \& to NOT press button to Stimulus B (happy face) (No-go trials). Task comprised 4 runs of 3 minutes \& 8 seconds each. Each run included 36 target (Go) \& 13 non target (No-go) stimuli. The stimuli were presented for 500ms with 2 to 14.5 inter-stimulus interval fixation cross in between. Target stimuli were pseudo-randomized across runs so that each participant was presented with 2 Happy Go \& 2 Neutral Go conditions. SSRT: White circle was shown for 500ms, followed by left (\<)/right (\>) arrow. When an arrow was presented, participants were to respond fast with their index/middle finger. A titration procedure with 4 staircases that started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms determined participant's SSRT. Scores were not bounded by a minimum or maximum range, higher fMRI BOLD activation scores indicate increased brain blood flow, which reflects brain activity.

    Time frame: At baseline (Day 0), and week 3 (Day 21) of the treatment phase

  2. Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11)

    A participant-rated scale was used to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/ always) and the scores were used to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance and cognitive instability impulsiveness) and 3 second-order factors ( motor impulsiveness, nonplanning impulsiveness and attentional impulsiveness). The total score ranged from 30 to 120 with higher scores indicating impulsive personality traits, and took 10 to 15 minutes to complete the BIS-11.

    Time frame: At baseline (Day 0), and Week 6 (Day 42) of the treatment.

  3. Change From Baseline to Week 3 in BIS-11

    A participant-rated scale was used to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/ always) and the scores were used to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance and cognitive instability impulsiveness) and 3 second-order factors ( motor impulsiveness, nonplanning impulsiveness and attentional impulsiveness). The total score ranged from 30 to 120 with higher scores indicating impulsive personality traits, and took 10 to 15 minutes to complete the BIS-11.

    Time frame: At baseline (Day 0), and Week 3 (Day 21) of the treatment.

  4. Change From Baseline to Week 6 in Go/No-go Task Behavior

    Brexpiprazole reduced impulsivity was measured by a change in false alarm rate on the Go/No-go task (a lower false alarm rate was suggestive of better inhibition). Participants were instructed to press a button as fast as they could to Stimulus A (eg, neutral face) that appeared on the screen (Go trials) and to NOT press a button to Stimulus B (eg, happy face) that appeared on the screen (No-go trials). The stimuli were presented randomly. The value calculated was the rate of incorrect response for each condition (Go and No-go).

    Time frame: At baseline (Day 0), week 6 (Day 42) of the treatment phase

  5. Change From Baseline to Week 3 in Go/No-go Task Behavior

    Brexpiprazole reduced impulsivity was measured by a change in false alarm rate on the Go/No-go task (a lower false alarm rate was suggestive of better inhibition). Participants were instructed to press a button as fast as they could to Stimulus A (eg, neutral face) that appeared on the screen (Go trials) and to NOT press a button to Stimulus B (eg, happy face) that appeared on the screen (No-go trials). The stimuli were presented randomly. The value calculated was the rate of incorrect response for each condition (Go and No-go).

    Time frame: At baseline (Day 0), and week 3 (Day 21) of the treatment phase

  6. Change From Baseline to Week 6 in Monetary Choice Questionnaire (MCQ) Score

    To measure "delay discounting" as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consisted of 27 choices between immediate and delayed rewards. The participants chose repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (ex: ''Would you prefer $27 today or $50 in 21 days?"). The answers provided an estimate of the participant's discounting rate. The discounting rate parameter takes values between 0 and 1 and higher discounting rates indicated impulsivity. It took 5 to10 minutes to complete the MCQ

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  7. Change From Baseline to Week 3 in MCQ Score

    To measure "delay discounting" as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consisted of 27 choices between immediate and delayed rewards. The participants chose repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (ex: ''Would you prefer $27 today or $50 in 21 days?"). The answers provided an estimate of the participant's discounting rate. The discounting rate parameter takes values between 0 and 1 and higher discounting rates indicated impulsivity.

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  8. Change From Baseline to Week 6 in Stop Signal Reaction Time Task (SSRT) Task Behavior

    Brexpiprazole reduced impulsivity was measured by a change in Stop Signal Reaction Time (SSRT) on the SSRT task (a lower SSRT was suggestive of better inhibition). A white circle was shown for 500ms, followed by a left (\<)/right (\>) arrow. When an arrow was presented, participants responded as fast as possible with their index/middle finger. A titration procedure with 4 staircases started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms to determine participant's SSRT. The tasks included 3 runs with 166 repetition times (TRs), TR=2s; 5 minutes, 32 seconds/run; 96 go trials, 32 stop trials/ run. The total task duration was 16 minutes \& 36 seconds. During scanning, the SSD was dynamically adjusted to yield a 50% successful inhibition rate, so that SSRT could be estimated for each participant. This resulted in approximately equal proportions of stop trials with \& without a response

    Time frame: At baseline (Day 0), and Week 6 (Day 42).

  9. Change From Baseline to Week 3 in SSRT Task Behavior

    Brexpiprazole reduced impulsivity was measured by a change in Stop Signal Reaction Time (SSRT) on the SSRT task (a lower SSRT was suggestive of better inhibition). A white circle was shown for 500ms, followed by a left (\<)/right (\>) arrow. When an arrow was presented, participants responded as fast as possible with their index/middle finger. A titration procedure with 4 staircases started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms to determine participant's SSRT. The tasks included 3 runs with 166 repetition times (TRs), TR=2s; 5 minutes, 32 seconds/run; 96 go trials, 32 stop trials/ run. The total task duration was 16 minutes \& 36 seconds. During scanning, the SSD was dynamically adjusted to yield a 50% successful inhibition rate, so that SSRT could be estimated for each participant. This resulted in approximately equal proportions of stop trials with \& without a response

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  10. Change From Baseline to Week 6 in Continuous Performance Task (CPT) Behavior

    The AX trials were "target trials" with a valid cue followed by a valid probe X. This feature was intended to encourage participants to "expect" a valid probe to follow a valid cue. A consequence of this manipulation was that participants developed a prepotency to respond with "target" responses on trials for which valid cues were presented. The cue was presented for 1000msec, the inter-stimulus interval was 2000msec, and the target was presented for 500msec with a response window of 1500msec. The ITI was 1200msec. Participants had to practice until criteria were obtained. In the AX-CPT task, the subjects were instructed to press the "Yes" button every time there is a blue letter 'X' (target) following a white letter 'A' (cue). During this task, any letter appears on the screen randomly. The value calculated was the rate of correct response for all the reaction of target trial.

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  11. Change From Baseline to Week 3 in CPT Behavior

    The AX trials were "target trials" with a valid cue followed by a valid probe X. This feature was intended to encourage participants to "expect" a valid probe to follow a valid cue. A consequence of this manipulation was that participants developed a prepotency to respond with "target" responses on trials for which valid cues were presented. The cue was presented for 1000msec, the inter-stimulus interval was 2000msec, and the target was presented for 500msec with a response window of 1500msec. The ITI was 1200msec. Participants had to practice until criteria were obtained. In the AX-CPT task, the subjects were instructed to press the "Yes" button every time there is a blue letter 'X' (target) following a white letter 'A' (cue). During this task, any letter appears on the screen randomly. The value calculated was the rate of correct response for all the reaction of target trial.

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  12. Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of 3 subscales containing 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. PANSS Positive and Negative subscale scores symptom constructs consisted of positive subscale (7 positive symptom constructs), negative subscale (7 negative symptom constructs), and general psychopathology subscale (16 symptom constructs). The possible maximum PANSS total score was 210; 30 indicating no symptoms; 210 indicating extremely severe symptoms.

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  13. Change From Baseline to Week 3 in PANSS Total Score

    The PANSS consisted of 3 subscales containing 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. PANSS Positive and Negative subscale scores symptom constructs consisted of positive subscale (7 positive symptom constructs), negative subscale (7 negative symptom constructs), and general psychopathology subscale (16 symptom constructs). The possible maximum PANSS total score was 210; 30 indicating no symptoms; 210 indicating extremely severe symptoms.

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  14. Change From Baseline to Week 6 in PANSS Positive Subscale Score

    PANSS consisted of positive subscales with 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  15. Change From Baseline to Week 3 in PANSS Positive Subscale Score

    PANSS consisted of positive subscales with 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  16. Change From Baseline to Week 6 in PANSS Negative Subscale Score

    PANSS consisted of negative subscale with 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  17. Change From Baseline to Week 3 in PANSS Negative Subscale Score

    PANSS consisted of negative subscale with 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  18. Change From Baseline to Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score

    The severity of illness for each participant was assessed. The rater or investigator's response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  19. Change From Baseline to Week 3 in CGI-S Score

    The severity of illness for each participant was assessed. The rater or investigator's response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  20. Clinical Global Impression - Improvement Scale (CGI-I) Score at Week 6

    To assess whether the total improvement was entirely due to drug treatment. The rater or investigator's response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared to the participant's condition at baseline (last available measurement at the baseline/Day 0 visit before the first dose of IMP).

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

  21. CGI-I Score at Week 3

    To assess whether the total improvement was entirely due to drug treatment. The rater or investigator's response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared to the participant's condition at baseline (last available measurement at the baseline/Day 0 visit before the first dose of IMP).

    Time frame: During trial visits from Day 0 to Week 3 (Day 21).

  22. Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP)

    A validated clinician-rated scale that measured personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment was rated as absent, mild, manifest, marked, severe, or very severe and were converted to a total score on a 100-point scale: 71 to 100 - mild functional difficulty, 31 to 70 - manifest disabilities of various degrees and 1 to 30 - minimal functioning that required intense support and/or supervision.

    Time frame: During trial visits from Day 0 to Week 6 (Day 42).

07

Results

Posted Sep 11, 2018

Participant flow

The study was conducted in the United States (US). 38 participants with schizophrenia with impulsivity were enrolled (signed informed consent) and randomized (1:1): 19 participants to brexpiprazole 2mg and 4mg treatment each; received at least 1 dose of Investigational medicinal product (IMP) for 6-week treatment phase in a double-blind design.

Participant flow — Overall Study
MilestoneBrexpiprazole 2 mgBrexpiprazole 4 mg
Started1919
Completed1610
Not completed39
Withdrew: Lost to follow-up12
Withdrew: Participant met withdrawal criteria13
Withdrew: Withdrawal by subject02
Withdrew: Lack of efficacy12

Outcome measures

PrimaryChange From Baseline Brain Activation in the Ventrolateral Prefrontal Cortex (VLPFC) Based on Change From Baseline to Week 6 in fMRI Blood Oxygen-level Dependent (BOLD) Activation Score in the Right VLPFC During Performance of the Go/No-go Task

To evaluate the effect of brexpiprazole on brain regions activated by impulsive behavior (specifically, activation of the right VLPFC). Assessed by fMRI measurements taken when participants perform tasks designed to assess impulsivity. The tasks to be performed in the scanner included the Go/No-go. Participants were asked to press a button as fast as they could to Stimulus A (eg, neutral face) that appeared on the screen (Go trials) \& to NOT press a button to Stimulus B (eg, happy face) that appeared on the screen (No-go trials). The Go trials were presented at a higher frequency (eg, 75% of the time) than the No-go trials to build up a pre-potent response/response bias. Scores were not bounded by a minimum or maximum range, higher fMRI BOLD activation scores indicate increased brain blood flow, which reflects brain activity.

Time frame:
At baseline (Day 0), and week 6 (Day 42) of the treatment phase
Reported as:
Least squares mean · units on a scale
Change From Baseline Brain Activation in the Ventrolateral Prefrontal Cortex (VLPFC) Based on Change From Baseline to Week 6 in fMRI Blood Oxygen-level Dependent (BOLD) Activation Score in the Right VLPFC During Performance of the Go/No-go Task
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
At Week 00.06450 ± 0.028150.06609 ± 0.02875
At Week 60.04949 ± 0.028780.04326 ± 0.03128
Statistical analysis
  • Brexpiprazole 2 mg vs Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.3992 (Test for Baseline vs. Week 6)
PrimaryChange From Baseline Brain Activation in the VLPFC Based on Change From Baseline to Week 6 in fMRI BOLD Activation Score in the Right VLPFC During Performance of the SSRT Task

To evaluate the effect of brexpiprazole on brain regions activated by impulsive behavior (specifically, activation of the right VLPFC). Assessed by fMRI measurements taken when participants performed impulsivity assessment tasks. A white circle was shown for 500ms, followed by a left (\<)/right (\>) arrow. When an arrow was presented, participants responded as fast as possible with their index/middle finger. A titration procedure with 4 staircases started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms to determine participant's SSRT. The tasks included 3 runs with 166 repetition times (TRs), TR=2s; 5 minutes, 32 seconds/run; 96 go trials, 32 stop trials/ run. The total task duration was 16 minutes \& 36 seconds. Scores were not bounded by a minimum or maximum range, higher fMRI BOLD activation scores indicate increased brain blood flow, which reflects brain activity.

Time frame:
At baseline (Day 0), and week 6 (Day 42) of the treatment phase
Reported as:
Least squares mean · units on a scale
Change From Baseline Brain Activation in the VLPFC Based on Change From Baseline to Week 6 in fMRI BOLD Activation Score in the Right VLPFC During Performance of the SSRT Task
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
At Week 00.05200 ± 0.029930.09485 ± 0.03428
At Week 6-0.00140 ± 0.030480.002815 ± 0.03541
Statistical analysis
  • Brexpiprazole 2 mg vs Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.0053 (Test for Baseline vs. Week 6)
SecondaryChange From Baseline to Week 3 in fMRI BOLD Activation Score in the Right VLPFC, Scanned by fMRI During Performance of Tasks Associated With Impulsivity (SSRT Task, Go/No-go Task)

Go/No-go: Participants were to press button fast to Stimulus A (neutral face) (Go trials) \& to NOT press button to Stimulus B (happy face) (No-go trials). Task comprised 4 runs of 3 minutes \& 8 seconds each. Each run included 36 target (Go) \& 13 non target (No-go) stimuli. The stimuli were presented for 500ms with 2 to 14.5 inter-stimulus interval fixation cross in between. Target stimuli were pseudo-randomized across runs so that each participant was presented with 2 Happy Go \& 2 Neutral Go conditions. SSRT: White circle was shown for 500ms, followed by left (\<)/right (\>) arrow. When an arrow was presented, participants were to respond fast with their index/middle finger. A titration procedure with 4 staircases that started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms determined participant's SSRT. Scores were not bounded by a minimum or maximum range, higher fMRI BOLD activation scores indicate increased brain blood flow, which reflects brain activity.

Time frame:
At baseline (Day 0), and week 3 (Day 21) of the treatment phase
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in fMRI BOLD Activation Score in the Right VLPFC, Scanned by fMRI During Performance of Tasks Associated With Impulsivity (SSRT Task, Go/No-go Task)
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
GNG; Week 00.06347 ± 0.028010.06553 ± 0.02869
GNG; Week 30.08523 ± 0.028010.04973 ± 0.02869
SSRT; Week 00.05376 ± 0.029030.09550 ± 0.03346
SSRT; Week 30.06398 ± 0.029790.02410 ± 0.03346
SecondaryChange From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11)

A participant-rated scale was used to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/ always) and the scores were used to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance and cognitive instability impulsiveness) and 3 second-order factors ( motor impulsiveness, nonplanning impulsiveness and attentional impulsiveness). The total score ranged from 30 to 120 with higher scores indicating impulsive personality traits, and took 10 to 15 minutes to complete the BIS-11.

Time frame:
At baseline (Day 0), and Week 6 (Day 42) of the treatment.
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11)
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in Barratt Impulsiveness Scale (BIS-11)-2.6 ± 1.81.0 ± 2.0
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.1559
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.6201
SecondaryChange From Baseline to Week 3 in BIS-11

A participant-rated scale was used to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/ always) and the scores were used to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance and cognitive instability impulsiveness) and 3 second-order factors ( motor impulsiveness, nonplanning impulsiveness and attentional impulsiveness). The total score ranged from 30 to 120 with higher scores indicating impulsive personality traits, and took 10 to 15 minutes to complete the BIS-11.

Time frame:
At baseline (Day 0), and Week 3 (Day 21) of the treatment.
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in BIS-11
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in BIS-11-2.4 ± 1.7-2.3 ± 1.7
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.1642
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.1873
SecondaryChange From Baseline to Week 6 in Go/No-go Task Behavior

Brexpiprazole reduced impulsivity was measured by a change in false alarm rate on the Go/No-go task (a lower false alarm rate was suggestive of better inhibition). Participants were instructed to press a button as fast as they could to Stimulus A (eg, neutral face) that appeared on the screen (Go trials) and to NOT press a button to Stimulus B (eg, happy face) that appeared on the screen (No-go trials). The stimuli were presented randomly. The value calculated was the rate of incorrect response for each condition (Go and No-go).

Time frame:
At baseline (Day 0), week 6 (Day 42) of the treatment phase
Reported as:
Mean · Millisecond
Change From Baseline to Week 6 in Go/No-go Task Behavior
MillisecondBrexpiprazole 2 mgBrexpiprazole 4 mg
At Week 00.11 ± 0.080.09 ± 0.06
At Week 60.08 ± 0.090.12 ± 0.17
SecondaryChange From Baseline to Week 3 in Go/No-go Task Behavior

Brexpiprazole reduced impulsivity was measured by a change in false alarm rate on the Go/No-go task (a lower false alarm rate was suggestive of better inhibition). Participants were instructed to press a button as fast as they could to Stimulus A (eg, neutral face) that appeared on the screen (Go trials) and to NOT press a button to Stimulus B (eg, happy face) that appeared on the screen (No-go trials). The stimuli were presented randomly. The value calculated was the rate of incorrect response for each condition (Go and No-go).

Time frame:
At baseline (Day 0), and week 3 (Day 21) of the treatment phase
Reported as:
Mean · Millisecond
Change From Baseline to Week 3 in Go/No-go Task Behavior
MillisecondBrexpiprazole 2 mgBrexpiprazole 4 mg
Week 00.11 ± 0.080.09 ± 0.06
Week 30.10 ± 0.130.15 ± 0.14
SecondaryChange From Baseline to Week 6 in Monetary Choice Questionnaire (MCQ) Score

To measure "delay discounting" as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consisted of 27 choices between immediate and delayed rewards. The participants chose repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (ex: ''Would you prefer $27 today or $50 in 21 days?"). The answers provided an estimate of the participant's discounting rate. The discounting rate parameter takes values between 0 and 1 and higher discounting rates indicated impulsivity. It took 5 to10 minutes to complete the MCQ

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in Monetary Choice Questionnaire (MCQ) Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in Monetary Choice Questionnaire (MCQ) Score-0.019762 ± 0.0152130.023685 ± 0.017103
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.2061
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.1778
SecondaryChange From Baseline to Week 3 in MCQ Score

To measure "delay discounting" as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consisted of 27 choices between immediate and delayed rewards. The participants chose repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (ex: ''Would you prefer $27 today or $50 in 21 days?"). The answers provided an estimate of the participant's discounting rate. The discounting rate parameter takes values between 0 and 1 and higher discounting rates indicated impulsivity.

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in MCQ Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in MCQ Score-0.012073 ± 0.0145580.014520 ± 0.014891
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.4138
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.3375
SecondaryChange From Baseline to Week 6 in Stop Signal Reaction Time Task (SSRT) Task Behavior

Brexpiprazole reduced impulsivity was measured by a change in Stop Signal Reaction Time (SSRT) on the SSRT task (a lower SSRT was suggestive of better inhibition). A white circle was shown for 500ms, followed by a left (\<)/right (\>) arrow. When an arrow was presented, participants responded as fast as possible with their index/middle finger. A titration procedure with 4 staircases started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms to determine participant's SSRT. The tasks included 3 runs with 166 repetition times (TRs), TR=2s; 5 minutes, 32 seconds/run; 96 go trials, 32 stop trials/ run. The total task duration was 16 minutes \& 36 seconds. During scanning, the SSD was dynamically adjusted to yield a 50% successful inhibition rate, so that SSRT could be estimated for each participant. This resulted in approximately equal proportions of stop trials with \& without a response

Time frame:
At baseline (Day 0), and Week 6 (Day 42).
Reported as:
Mean · Millisecond
Change From Baseline to Week 6 in Stop Signal Reaction Time Task (SSRT) Task Behavior
MillisecondBrexpiprazole 2 mgBrexpiprazole 4 mg
At Week 0357.63 ± 61.51323.25 ± 56.59
At Week 6299.68 ± 67.77302.57 ± 34.68
SecondaryChange From Baseline to Week 3 in SSRT Task Behavior

Brexpiprazole reduced impulsivity was measured by a change in Stop Signal Reaction Time (SSRT) on the SSRT task (a lower SSRT was suggestive of better inhibition). A white circle was shown for 500ms, followed by a left (\<)/right (\>) arrow. When an arrow was presented, participants responded as fast as possible with their index/middle finger. A titration procedure with 4 staircases started with stop signal delay (SSD) values of 100, 150, 200 \& 250ms to determine participant's SSRT. The tasks included 3 runs with 166 repetition times (TRs), TR=2s; 5 minutes, 32 seconds/run; 96 go trials, 32 stop trials/ run. The total task duration was 16 minutes \& 36 seconds. During scanning, the SSD was dynamically adjusted to yield a 50% successful inhibition rate, so that SSRT could be estimated for each participant. This resulted in approximately equal proportions of stop trials with \& without a response

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Median · Millisecond
Change From Baseline to Week 3 in SSRT Task Behavior
MillisecondBrexpiprazole 2 mgBrexpiprazole 4 mg
At week 0357.63 ± 61.51323.25 ± 56.59
At week 3337.62 ± 76.23328.05 ± 54.62
SecondaryChange From Baseline to Week 6 in Continuous Performance Task (CPT) Behavior

The AX trials were "target trials" with a valid cue followed by a valid probe X. This feature was intended to encourage participants to "expect" a valid probe to follow a valid cue. A consequence of this manipulation was that participants developed a prepotency to respond with "target" responses on trials for which valid cues were presented. The cue was presented for 1000msec, the inter-stimulus interval was 2000msec, and the target was presented for 500msec with a response window of 1500msec. The ITI was 1200msec. Participants had to practice until criteria were obtained. In the AX-CPT task, the subjects were instructed to press the "Yes" button every time there is a blue letter 'X' (target) following a white letter 'A' (cue). During this task, any letter appears on the screen randomly. The value calculated was the rate of correct response for all the reaction of target trial.

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · Rate of correct response
Change From Baseline to Week 6 in Continuous Performance Task (CPT) Behavior
Rate of correct responseBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in Continuous Performance Task (CPT) Behavior-0.70 ± 3.50-0.87 ± 4.06
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.8437
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.8318
SecondaryChange From Baseline to Week 3 in CPT Behavior

The AX trials were "target trials" with a valid cue followed by a valid probe X. This feature was intended to encourage participants to "expect" a valid probe to follow a valid cue. A consequence of this manipulation was that participants developed a prepotency to respond with "target" responses on trials for which valid cues were presented. The cue was presented for 1000msec, the inter-stimulus interval was 2000msec, and the target was presented for 500msec with a response window of 1500msec. The ITI was 1200msec. Participants had to practice until criteria were obtained. In the AX-CPT task, the subjects were instructed to press the "Yes" button every time there is a blue letter 'X' (target) following a white letter 'A' (cue). During this task, any letter appears on the screen randomly. The value calculated was the rate of correct response for all the reaction of target trial.

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Least squares mean · Rate of correct response
Change From Baseline to Week 3 in CPT Behavior
Rate of correct responseBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in CPT Behavior1.79 ± 4.14-0.61 ± 4.08
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.6697
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.8829
SecondaryChange From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of 3 subscales containing 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. PANSS Positive and Negative subscale scores symptom constructs consisted of positive subscale (7 positive symptom constructs), negative subscale (7 negative symptom constructs), and general psychopathology subscale (16 symptom constructs). The possible maximum PANSS total score was 210; 30 indicating no symptoms; 210 indicating extremely severe symptoms.

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score-2.4 ± 1.9-4.1 ± 2.1
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.2301
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.0599
SecondaryChange From Baseline to Week 3 in PANSS Total Score

The PANSS consisted of 3 subscales containing 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. PANSS Positive and Negative subscale scores symptom constructs consisted of positive subscale (7 positive symptom constructs), negative subscale (7 negative symptom constructs), and general psychopathology subscale (16 symptom constructs). The possible maximum PANSS total score was 210; 30 indicating no symptoms; 210 indicating extremely severe symptoms.

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in PANSS Total Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in PANSS Total Score-2.0 ± 1.4-2.3 ± 1.4
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.1595
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.1211
SecondaryChange From Baseline to Week 6 in PANSS Positive Subscale Score

PANSS consisted of positive subscales with 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in PANSS Positive Subscale Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in PANSS Positive Subscale Score-1.4 ± 0.9-1.3 ± 1.0
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.1322
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.2113
SecondaryChange From Baseline to Week 3 in PANSS Positive Subscale Score

PANSS consisted of positive subscales with 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in PANSS Positive Subscale Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in PANSS Positive Subscale Score-1.2 ± 0.6-1.3 ± 0.6
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.0578
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.0588
SecondaryChange From Baseline to Week 6 in PANSS Negative Subscale Score

PANSS consisted of negative subscale with 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in PANSS Negative Subscale Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in PANSS Negative Subscale Score-0.9 ± 0.60.2 ± 0.6
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.1666
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.7670
SecondaryChange From Baseline to Week 3 in PANSS Negative Subscale Score

PANSS consisted of negative subscale with 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking). Each item was scored using a scale of 1 to 7 (a higher score indicated increased severity). The maximum subscale score was 49; 7 indicated no symptoms; 49 indicated extreme severity.

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in PANSS Negative Subscale Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in PANSS Negative Subscale Score0.2 ± 0.70.8 ± 0.7
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.7178
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.2336
SecondaryChange From Baseline to Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score

The severity of illness for each participant was assessed. The rater or investigator's response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score-0.1 ± 0.10.0 ± 0.2
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.6558
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.9058
SecondaryChange From Baseline to Week 3 in CGI-S Score

The severity of illness for each participant was assessed. The rater or investigator's response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 3 in CGI-S Score
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 3 in CGI-S Score-0.3 ± 0.1-0.1 ± 0.1
Statistical analysis
  • Brexpiprazole 2 mg · Mixed Models Analysis · p = 0.0078
  • Brexpiprazole 4 mg · Mixed Models Analysis · p = 0.4272
SecondaryClinical Global Impression - Improvement Scale (CGI-I) Score at Week 6

To assess whether the total improvement was entirely due to drug treatment. The rater or investigator's response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared to the participant's condition at baseline (last available measurement at the baseline/Day 0 visit before the first dose of IMP).

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Mean · units on a scale
Clinical Global Impression - Improvement Scale (CGI-I) Score at Week 6
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Clinical Global Impression - Improvement Scale (CGI-I) Score at Week 63.6 ± 1.03.9 ± 0.5
SecondaryCGI-I Score at Week 3

To assess whether the total improvement was entirely due to drug treatment. The rater or investigator's response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared to the participant's condition at baseline (last available measurement at the baseline/Day 0 visit before the first dose of IMP).

Time frame:
During trial visits from Day 0 to Week 3 (Day 21).
Reported as:
Mean · units on a scale
CGI-I Score at Week 3
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
CGI-I Score at Week 33.7 ± 0.83.8 ± 0.5
SecondaryChange From Baseline to Week 6 in Personal and Social Performance Scale (PSP)

A validated clinician-rated scale that measured personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment was rated as absent, mild, manifest, marked, severe, or very severe and were converted to a total score on a 100-point scale: 71 to 100 - mild functional difficulty, 31 to 70 - manifest disabilities of various degrees and 1 to 30 - minimal functioning that required intense support and/or supervision.

Time frame:
During trial visits from Day 0 to Week 6 (Day 42).
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP)
units on a scaleBrexpiprazole 2 mgBrexpiprazole 4 mg
Change From Baseline to Week 6 in Personal and Social Performance Scale (PSP)1.7 ± 1.6-0.0 ± 1.7

Adverse events

Collected over Trial visits (Days 0 to 42). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 2 mg0/19 (0%)0/19 (0%)13/19 (68.4%)
Brexpiprazole 4 mg0/19 (0%)0/19 (0%)14/19 (73.7%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventBrexpiprazole 2 mgBrexpiprazole 4 mg
HeadacheNervous system disorders3/192/19
NasopharyngitisInfections and infestations2/190/19
Back painMusculoskeletal and connective tissue disorders1/192/19
AgitationPsychiatric disorders0/192/19
AnxietyPsychiatric disorders0/192/19
InsomniaPsychiatric disorders2/192/19
IrritabilityPsychiatric disorders2/190/19
RestlessnessPsychiatric disorders2/190/19
Abdominal pain upperGastrointestinal disorders1/191/19
DyspepsiaGastrointestinal disorders1/191/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brexpiprazole 2 mgBrexpiprazole 4 mgTotal
<=18 years000
Between 18 and 65 years191938
>=65 years000
Age, Continuous
Age, Continuous(Years)Brexpiprazole 2 mgBrexpiprazole 4 mgTotal
Mean45.2 ± 10.047.4 ± 11.146.3 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 2 mgBrexpiprazole 4 mgTotal
Female336
Male161632
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole 2 mgBrexpiprazole 4 mgTotal
United States191938
Race
Race(participants)Brexpiprazole 2 mgBrexpiprazole 4 mgTotal
Caucasian (White)6713
Black or African or American81220
Asian202
Others303
Ethinicity
Ethinicity(participants)Brexpiprazole 2 mgBrexpiprazole 4 mgTotal
Hispanic/Latino437
Not Hispanic/Latino151631
08

Study locations

1 site
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
09

References and documents

Publications

  • van Erp TG, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, Potkin SG. Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study. Psychiatry Res Neuroimaging. 2020 Jul 30;301:111085. doi: 10.1016/j.pscychresns.2020.111085. Epub 2020 May 5. PubMed 32450497 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2014
First posted
Jul 21, 2014
Start
Feb 2015
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Sep 11, 2018
Last update
Nov 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02194933
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Feb 2015
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Sep 11, 2018
Last update
Nov 8, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion